Jefferies Upgrades Oscar Health#
Jefferies has upgraded Oscar Health Inc. from an Underperform rating to Hold, increasing its price target from $10.00 to $16.00. Currently, the stock trades at $15.79, which is close to this new target. Despite this, analysis suggests that Oscar Health may still be undervalued, with a fair value estimated at $19.81.
Positive Pricing Outlook#
The firm’s analysis indicates that Oscar Health is likely pricing its services effectively to meet its 2026 margin goals. Conversations within the industry and data trends show that market enrollment is performing better than expected, which is a positive sign for the company’s financial health. Jefferies believes that Oscar Health is gaining a larger share of favorable customers, even after adjusting for risk factors.
Market Challenges Ahead#
Despite the optimistic outlook, Jefferies warns that the health insurance exchange market remains fragile. They note that Oscar Health’s growth in low-cost premium members could increase risks related to market health, especially if cost-sharing measures change or if the Centers for Medicare and Medicaid Services adjust their policies.
Recent Financial Performance#
In its latest financial report for the fourth quarter of 2025, Oscar Health fell short of earnings and revenue expectations. The company reported an earnings per share (EPS) of -$1.24, which was below the anticipated -$0.89. Revenue also missed estimates, coming in at $2.81 billion instead of the expected $3.11 billion. Despite these setbacks, Oscar Health's stock saw a rise in pre-market trading, possibly due to strong future guidance and strategic initiatives.
Additional Upgrades#
In related news, Raymond James has also upgraded Oscar Health’s stock rating from Market Perform to Outperform, setting a price target of $18.00. They cited attractive valuation and improving margins in the Affordable Care Act exchange market as key reasons for this upgrade.